Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $9.9400 (-5.15%) ($9.5800 - $10.4800) on Mon. Apr. 13, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.04% (three month average) | RSI | 64 | Latest Price | $9.9400(-5.15%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 1.2% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(57%) ARKK(54%) IBB(54%) IBUY(52%) | Factors Impacting TGTX price | TGTX will decline at least -3.52% in a week (0% probabilities). VIXM(-33%) VXX(-31%) UUP(-15%) TLT(-1%) TBT(1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.52% (StdDev 7.04%) | Hourly BBV | 0 () | Intraday Trend | -5.2% | | | |
|
5 Day Moving Average | $9.97(-0.3%) | 10 Day Moving Average | $9.74(2.05%) | 20 Day Moving Average | $9.22(7.81%) | To recent high | -37.8% | To recent low | 39.2% | Market Cap | $1.259b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |